Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial
- Silvia Maria Lavezzi
- , Jan de Jong
- , Martine Neyens
- , Paula Cramer
- , Fatih Demirkan
- , Graeme Fraser
- , Nancy Bartlett
- , Marie Sarah Dilhuydy
- , Javier Loscertales
- , Abraham Avigdor
- , Simon Rule
- , Olga Samoilova
- , Andre Goy
- , Siddhartha Ganguly
- , Mariya Salman
- , Angela Howes
- , Michelle Mahler
- , Giuseppe De Nicolao
- , Italo Poggesi*
*Corresponding author for this work
- University of Pavia
- PAREXEL International (IRL) Limited
- Janssen R&D
- Johnson & Johnson
- University of Cologne
- Dokuz Eylul University
- McMaster University
- Washington University St. Louis
- Hôpital du Haut-Lévêque
- Hospital Universitario de la Princesa
- University Hospitals Plymouth NHS Trust
- Nizhny Novgorod Regional Clinical Hospital
- Hackensack University Medical Center
- University of Kansas
- Janssen R & D
Research output: Contribution to journal › Article › peer-review
6
Scopus
citations